Pelthos Therapeutics Inc. filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 12, 2026, to register 500,000 shares of common stock issuable under its newly adopted 2026 Equity Incentive Plan.

Key Highlights

  • Shares registered: 500,000 shares of common stock, par value $0.0001 per share, are covered by this registration statement.
  • Plan name: The shares are issuable under the Pelthos Therapeutics Inc. 2026 Equity Incentive Plan.
  • Board approval: The board of directors approved the Plan on August 4, 2026.
  • Stockholder approval: Stockholders approved the Plan at the 2026 annual meeting held on September 29, 2026, upon which the Plan became effective.
  • Company classification: Pelthos Therapeutics is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, according to the filing.
  • Agent for service: John M. Gay, Chief Financial Officer, is listed as the agent for service, based in Durham, North Carolina.

Pelthos Therapeutics Registers Equity Incentive Shares for 2026 Plan Participants

Pelthos Therapeutics Inc., a Nevada corporation headquartered at 4020 Stirrup Creek Drive, Suite 110, Durham, North Carolina 27703, filed a registration statement on Form S-8 with the Securities and Exchange Commission on November 12, 2026. According to the filing, the registration covers 500,000 shares of common stock, par value $0.0001 per share, that may be issued to plan participants under the company's 2026 Equity Incentive Plan. The filing does not disclose a ticker or exchange listing in its registered-securities table, and no exchange or ticker symbol is stated in the filing text.

The filing states that the company's board of directors approved the 2026 Equity Incentive Plan on August 4, 2026, and that the plan became effective following stockholder approval at the company's 2026 annual meeting of stockholders, held on September 29, 2026. Documents containing plan-specific information required under Section 10(a) of the Securities Act of 1933 will be delivered directly to plan participants, the registrant disclosed, rather than filed separately with the Commission.

The registration statement incorporates by reference several previously filed documents, including the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (filed March 19, 2026), Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, and multiple Current Reports on Form 8-K filed between January 2, 2026, and October 30, 2026. The filing also incorporates the description of the company's common stock contained in its Form 8-A filed on February 15, 2024. The indemnification section of the filing describes provisions under Nevada Revised Statutes applicable to the company's directors and officers, and states that the registrant has entered into indemnification agreements with each of its directors and executive officers.

What Was Disclosed

Pelthos Therapeutics filed a Form S-8 on November 12, 2026, registering 500,000 shares of common stock, par value $0.0001 per share, for issuance under its 2026 Equity Incentive Plan, which became effective following stockholder approval on September 29, 2026.